Addressing a chronically overlooked group in the nutritional supplement space is working out well for Nutritional Growth Solutions (ASX: NGS).
The supplement company is focused on improving the health of children aged 3-12 years old who do not meet the criteria for growth hormone therapy. A group that has been long overlooked in terms of dietary supplementation is being afforded options with the NGS range of Health Height shakes. The shakes are clinically proven to increase growth in children by up to 34%.
The Company has today announced that they have surpassed USD $500,000 in Healthy Height wholesale sales in Italy since launching there in March 2021.
NGS chose Italy as an initial launch point into Europe due to its large child population of 8.2 million under the age of 14. The Company secured distribution partner Dicofarm to distribute the product to pharmacies and health food stores across the country under the name “Dico Up” and is reaping the rewards.
Liron Fendell, CEO and Managing Director of NGS said: “To surpass USD $500,000 in wholesale sales in three-months, in a new region, is a big milestone for our company and shows there is a genuine need for nutritional products that support growth development in children.
“Our patented Health Heigh formula was developed over 20 years by leading paediatric specialists from the world-renowned Schneider Children’s Medical Centre in Israel and is clinically proven to improve growth in children through shakes and foods that contain specific key nutrients needed for growth development.
“We look forward to expanding our footprint in Europe to assist even more children reach their height potential.”
In recent months NGS has also released a snack bar version adding value to their range available in North America.
The market has reacted well to this news with NGS shares trading 21% higher since this morning’s announcement.
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
- Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
- How this company is developing medtech to support Indigenous community health - August 22, 2022
- A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
Leave a Comment
You must be logged in to post a comment.